The role of new tyrosine kinase inhibitors in chronic myeloid leukemia

Cancer Journal (United States)

Volumn 22, Issue 1, 2016, Pages 40-50

  Pophali, Priyanka A ^a   Patnaik, Mrinal M ^a  

^a MAYO CLINIC   (United States)

Author keywords

BCR ABL1; chronic myeloid leukemia; tyrosine kinase inhibitors

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; BILIRUBIN; BOSUTINIB; CREATININE; DANUSERTIB; DASATINIB; GNF 2; GNF 5; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REBASTINIB; SGX 70393; TG 101223; TOZASERTIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; [4 [2 (1H INDAZOL 3 YL)VINYL]PHENYL](1 PIPERAZINYL)METHANONE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTERY OCCLUSION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRADYCARDIA; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; EDEMA; EYE TOXICITY; FATIGUE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEADACHE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKEMIA RELAPSE; MULTICENTER STUDY (TOPIC); MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PANCREATITIS; PATIENT SATISFACTION; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SUDDEN DEATH; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VENOUS THROMBOEMBOLISM; VOMITING; DRUG DEVELOPMENT; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MORTALITY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DISCOVERY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84957658015     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000165     Document Type: Review

References (88)

1. Rowley JD,. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243: 290-293.
2. Ben-Neriah Y, Daley GQ, Mes-Masson AM, The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986; 233: 212-214.
3. Daley GQ, van Etten RA, Baltimore D,. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990; 247: 824-830.
4. Shtivelman E, Lifshitz B, Gale RP, Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985; 315: 550-554.
5. Bedi A, Zehnbauer BA, Barber JP, Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994; 83: 2038-2044.
6. Melo JV,. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996; 88: 2375-2384.
7. Goldman JM,. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010; 47: 302-311.
8. Talpaz M, Kantarjian HM, McCredie KB, Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987; 69: 1280-1288.
9. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst. 1997; 89: 1616-1620.
10. Bonifazi F, de Vivo A, Rosti G, Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001; 98: 3074-3081.
11. Guilhot F, Chastang C, Michallet M, Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997; 337: 223-229.
12. O'Brien SG, Guilhot F, Larson RA, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004.
13. Druker BJ, Guilhot F, O'Brien SG, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
14. Gorre ME, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293: 876-880.
15. Shah NP, Sawyers CL,. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003; 22: 7389-7395.
16. Jabbour E, Parikh SA, Kantarjian H, Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011; 25: 981-995.
17. Deininger M, O'Brien SG, Guilhot F, International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH 2009 Annual Meeting Abstracts. Blood 2009; 114: 1126.
18. Jabbour E, Kantarjian HM, Saglio G, Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014; 123: 494-500.
19. Hughes TP, Saglio G, Kantarjian HM, Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014; 123: 1353-1360.
20. Marin D, Hedgley C, Clark RE, Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012; 120: 291-294.
21. Hochhaus A, O'Brien SG, Guilhot F, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23: 1054-1061.
22. Hochhaus A, Saglio G, Larson RA, Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013; 121: 3703-3708.
23. Kalmanti L, Saussele S, Lauseker M, Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015; 29: 1123-1132.
24. Castagnetti F, Gugliotta G, Breccia M, Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015; 29: 1823-1831.
25. Hughes T, Saglio G, Branford S, Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009; 27: 4204-4210.
26. Saglio G, Kim DW, Issaragrisil S, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-2259.
27. Larson RA, Kim DW, Issaragrilsil S, Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f/u) of ENESTnd. ASH 2014 Annual Meeting Abstracts. Blood 2014; 124: 4541.
28. Larson RA, Kim DW, Jootar S, ENESTnd 5-year (y) update: long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM). J Clin Oncol. (Meeting Abstracts) May 2014; 32:suppl: 7073.
29. Delphine R, Gautier J, Breccia M, Incidence of hyperglycemia by 3 years in patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib (NIL) or imatinib (IM) in ΝSΤnd. ASH 2012 Annual Meeting Abstracts. Blood 2015; 125: 2771-2778.
30. Muller MC, Cortes JE, Kim DW, Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009; 114: 4944-4953.
31. Shah NP, Guilhot F, Cortes JE, Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014; 123: 2317-2324.
32. Kantarjian H, Shah NP, Hochhaus A, Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362: 2260-2270.
33. Kantarjian HM, Shah NP, Cortes JE, Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119: 1123-1129.
34. Cortes JE, Hochhaus A, Kim DW, Four-year (Yr) follow-up of patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. ASH 2013 Annual Meeting Abstracts. Blood 2013; 122: 653.
35. Cortes JE, Kim DW, Kantarjian HM, Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012; 30: 3486-3492.
36. Cortes JE, Kantarjian H, Shah NP, Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367: 2075-2088.
37. Cortes JE, Kim DW, Pinilla-Ibarz J, A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013; 369: 1783-1796.
38. Gainor JF, Chabner BA,. Ponatinib: accelerated disapproval. Oncologist. 2015; 20: 847-848.
39. Marin D, Ibrahim AR, Goldman JM,. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol. 2011; 29: 3944-3945.
40. Yeung DT, Osborn MP, White DL, TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015; 125: 915-923.
41. Kantarjian HM, Hochhaus A, Saglio G, Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12: 841-851.
42. Tefferi A, Kantarjian H, Rajkumar SV, In Support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015; 90: 996-1000.
43. Mahon FX, Rea D, Guilhot J, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11: 1029-1035.
44. Prost S, Relouzat F, Spentchian M, Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature. 2015; 525: 380-383.
45. Paquette RL, Shah NP, Sawyers CL, PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. ASH 2007 Annual Meeting Abstracts. Blood 2007; 110: 1030.
46. Eide CA, Adrian LT, Tyner JW, The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011; 71: 3189-3195.
47. Shen Y, Shi X, Pan J,. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRalpha. PLoS One. 2013; 8: e73059.
48. Wylie A SJ, Berellini G, ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. ASH 2014 Annual Meeting Abstracts. Blood 2014; 124: 398.
49. Cortes J SG, Baccarani M, Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). ASH 2014 Annual Meeting Abstracts. Blood. 2014; 124: 152.
50. Brummendorf TH, Cortes JE, de Souza CA, Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015; 168: 69-81.
51. Novartis. Gleevac: prescribing information. 2015. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021588s009lbl.pdf. Last accessed Aug. 30, 2015.
52. Squibb BM,. Sprycel: full prescribing information. 2015. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/021986s016s017lbledt.pdf. Last accessed Aug. 30, 2015.
53. Novartis. Tasigna: full prescribing information. 2015. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/022068s020lbl.pdf. Last accessed Aug. 30 2015.
54. Pfizer Laboratories Div Pfizer Inc. Bosulif: full prescribing information. 2014. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/203341s002lbl.pdf. Last accessed Aug. 30 2015.
55. Ariad. Iclusig: full prescribing information. 2014. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/203469s009lbl.pdf. Last accessed Aug. 30, 2015.
56. Kamath AV, Wang J, Lee FY, Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008; 61: 365-376.
57. Xia B, Heimbach T, He H, Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharm Drug Dispos. 2012; 33: 536-549.
58. Neville K, Parise RA, Thompson P, Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res. 2004; 10: 2525-2529.
59. Porkka K, Koskenvesa P, Lundan T, Dasatinib crosses the Blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112: 1005-1012.
60. Reinwald M, Schleyer E, Kiewe P, Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation. Biomed Res Int. 2014; 2014: 637059.
61. Liang S, Pong K, Gonzales C, Neuroprotective profile of novel SRC kinase inhibitors in rodent models of cerebral ischemia. J Pharmacol Exp Ther. 2009; 331: 827-835.
62. Baccarani M, Deininger MW, Rosti G, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122: 872-884.
63. NCCN. NCCN Clinical Practice Guidelines in Oncology: chronic myelogenous leukemia. Version I.2016. 2016. Available at http://www.nccn.org/professionals/physician-gls/PDF/cml.pdf. Last accessed Aug. 30 2015.
64. O'Hare T, Eide CA, Deininger MW,. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007; 110: 2242-2249.
65. Redaelli S, Piazza R, Rostagno R, Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009; 27: 469-471.
66. Branford S, Melo JV, Hughes TP,. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009; 114: 5426-5435.
67. Jabbour E, Branford S, Saglio G, Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011; 117: 1800-1811.
68. Soverini S, Hochhaus A, Nicolini FE, BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011; 118: 1208-1215.
69. O'Brien S, Berman E, Moore JO, NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw. 2011; 9 (Suppl 2): S1-S25.
70. Cortes JE, Pinilla-Ibarz J, Ponatinib in patients (pts) with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 2-year follow-up of the PACE trial [abstract]. Blood. 2013: 122.
71. Cortes J, Lipton JH, Rea D, Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012; 120: 2573-2580.
72. Cortes J, Digumarti R, Parikh PM, Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013; 88: 350-354.
73. Alvandi F, Kwitkowski VE, Ko CW, U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist. 2014; 19: 94-99.
74. Cortes JE, Kantarjian HM, Rea D, Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: results with 24 months of follow-up. Cancer. 2015; 121: 1637-1644.
75. Seymour JF, Kim DW, Rubin E, A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2014; 4: e238.
76. Tanaka R, Squires MS, Kimura S, Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood. 2010; 116: 2089-2095.
77. Anna M, Eiring Ira L, Kraft Brent DG, BP5-087, a novel STAT3 inhibitor, combines with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia [abstract]. Blood. 2013; 122.
78. Eiring AM, Page BD, Kraft IL, Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2015; 29: 586-597.
79. Wu J, Meng F, Ying Y, ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells. Leukemia. 2010; 24: 869-872.
80. O'Hare T, Eide C, Tyner J, SGX70393 inhibits the T315I mutant of Bcr-Abl kinase and pre-empts drug resistance when combined with nilotinib or dasatinib. Mol Cancer Ther. 2007; 6 (11 Supplement): A259.
81. Zhu H, Hanna E, Lohse D, In vitro and in vivo inhibition of the T315I mutant BCR/ABL kinase. ASH 2006 Annual Meeting Abstracts. Blood 2006; 108: 2182.
82. Zhang J, Adrian FJ, Jahnke W, Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010; 463: 501-506.
83. + leukemias. Blood. 2014; 123: 3296-3304.
84. Shi R, Lin J, Guo Y, The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells. Pharmazie. 2014; 69: 346-352.
85. Shiotsu Y, Kiyoi H, Ishikawa Y, KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009; 114: 1607-1617.
86. + leukemia cells in vitro and in vivo. Clin Cancer Res. 2011; 17: 3219-3232.
87. Quintas-Cardama A, Cortes J,. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009; 113: 1619-1630.
88. Hantschel O, Grebien F, Superti-Furga G,. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 2012; 72: 4890-4895.